Taysha Gene Therapies (NASDAQ:TSHA) Issues Quarterly Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) issued its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%.

Taysha Gene Therapies Stock Down 3.2 %

Taysha Gene Therapies stock traded down $0.06 during mid-day trading on Wednesday, reaching $1.65. 355,961 shares of the company were exchanged, compared to its average volume of 2,060,365. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The business has a fifty day moving average of $1.69 and a 200 day moving average of $1.99. The firm has a market cap of $337.13 million, a P/E ratio of 2.61 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Analyst Ratings Changes

TSHA has been the subject of several recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Chardan Capital reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.